Ales Vicha1, Zdenek Musil, Karel Pacak. 1. Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University, University Hospital Motol, Czech Republic.
Abstract
PURPOSE OF REVIEW: To summarize the recent advances in the genetics of pheochromocytoma and paraganglioma (PHEO/PGL), focusing on the new susceptibility genes and dividing PHEOs/PGLs into two groups based on their transcription profile. RECENT FINDINGS: Recently, TMEM127, MYC-associated factor X, and hypoxia-inducible factor (HIF) 2α have been described in the pathogenesis of PHEOs/PGLs. Thus, now about 30-40% of these tumors are linked to the germline mutations, which also include mutations in the VHL, RET, NF1, SDHx, and SDHAF2 genes. Furthermore, PHEOs/PGLs have been divided into two groups, cluster 1 (SDHx/VHL) and cluster 2 (RET/NF1), based on the transcription profile revealed by genome-wide expression microarray analysis. SUMMARY: PHEOs/PGLs are the most inherited tumors among (neuro)endocrine tumors. Future approaches in genetics, including whole-genome sequencing, will allow the discovery of additional PHEO/PGL susceptibility genes. The current division of PHEOs/PGLs into cluster 1 and 2 provides us with additional knowledge related to the pathogenesis of these tumors, including the introduction of new treatment options for patients with metastatic PHEOs/PGLs. New discoveries related to the role of the HIF-1/HIF-2α genes in the pathogenesis of almost all inherited PHEOs/PGLs may call for a new regrouping of these tumors and discoveries of new treatment targets.
PURPOSE OF REVIEW: To summarize the recent advances in the genetics of pheochromocytoma and paraganglioma (PHEO/PGL), focusing on the new susceptibility genes and dividing PHEOs/PGLs into two groups based on their transcription profile. RECENT FINDINGS: Recently, TMEM127, MYC-associated factor X, and hypoxia-inducible factor (HIF) 2α have been described in the pathogenesis of PHEOs/PGLs. Thus, now about 30-40% of these tumors are linked to the germline mutations, which also include mutations in the VHL, RET, NF1, SDHx, and SDHAF2 genes. Furthermore, PHEOs/PGLs have been divided into two groups, cluster 1 (SDHx/VHL) and cluster 2 (RET/NF1), based on the transcription profile revealed by genome-wide expression microarray analysis. SUMMARY:PHEOs/PGLs are the most inherited tumors among (neuro)endocrine tumors. Future approaches in genetics, including whole-genome sequencing, will allow the discovery of additional PHEO/PGL susceptibility genes. The current division of PHEOs/PGLs into cluster 1 and 2 provides us with additional knowledge related to the pathogenesis of these tumors, including the introduction of new treatment options for patients with metastatic PHEOs/PGLs. New discoveries related to the role of the HIF-1/HIF-2α genes in the pathogenesis of almost all inherited PHEOs/PGLs may call for a new regrouping of these tumors and discoveries of new treatment targets.
Authors: Denise A Chan; Patrick D Sutphin; Phuong Nguyen; Sandra Turcotte; Edwin W Lai; Alice Banh; Gloria E Reynolds; Jen-Tsan Chi; Jason Wu; David E Solow-Cordero; Muriel Bonnet; Jack U Flanagan; Donna M Bouley; Edward E Graves; William A Denny; Michael P Hay; Amato J Giaccia Journal: Sci Transl Med Date: 2011-08-03 Impact factor: 17.956
Authors: Li Yao; Francesca Schiavi; Alberto Cascon; Yuejuan Qin; Lucia Inglada-Pérez; Elizabeth E King; Rodrigo A Toledo; Tonino Ercolino; Elena Rapizzi; Christopher J Ricketts; Luigi Mori; Mara Giacchè; Antonella Mendola; Elisa Taschin; Francesca Boaretto; Paola Loli; Maurizio Iacobone; Gian-Paolo Rossi; Bernadette Biondi; José Viana Lima-Junior; Claudio E Kater; Marie Bex; Miikka Vikkula; Ashley B Grossman; Stephen B Gruber; Marta Barontini; Alexandre Persu; Maurizio Castellano; Sergio P A Toledo; Eamonn R Maher; Massimo Mannelli; Giuseppe Opocher; Mercedes Robledo; Patricia L M Dahia Journal: JAMA Date: 2010-12-15 Impact factor: 56.272
Authors: Yuejuan Qin; Li Yao; Elizabeth E King; Kalyan Buddavarapu; Romina E Lenci; E Sandra Chocron; James D Lechleiter; Meghan Sass; Neil Aronin; Francesca Schiavi; Francesca Boaretto; Giuseppe Opocher; Rodrigo A Toledo; Sergio P A Toledo; Charles Stiles; Ricardo C T Aguiar; Patricia L M Dahia Journal: Nat Genet Date: 2010-02-14 Impact factor: 38.330
Authors: Patricia L M Dahia; Ken N Ross; Matthew E Wright; César Y Hayashida; Sandro Santagata; Marta Barontini; Andrew L Kung; Gabriela Sanso; James F Powers; Arthur S Tischler; Richard Hodin; Shannon Heitritter; Francis Moore; Robert Dluhy; Julie Ann Sosa; I Tolgay Ocal; Diana E Benn; Deborah J Marsh; Bruce G Robinson; Katherine Schneider; Judy Garber; Seth M Arum; Márta Korbonits; Ashley Grossman; Pascal Pigny; Sérgio P A Toledo; Vania Nosé; Cheng Li; Charles D Stiles Journal: PLoS Genet Date: 2005-07-25 Impact factor: 5.917
Authors: Sílvia Cristina de Sousa Paredes; Sara Gomes de Campos Lopes; Isabel Maria Beleza Ferraz Torres; Marta de Lurdes Fernandes Alves Journal: Eur Endocrinol Date: 2020-04-01
Authors: T Vosecka; A Vicha; T Zelinka; P Jencova; K Pacak; J Duskova; J Benes; A Guha; L Stanek; M Kohoutova; Z Musil Journal: Neoplasma Date: 2017 Impact factor: 2.575
Authors: Adam C Millar; Ozgur Mete; Robert J Cusimano; Stephen E Fremes; Shaf Keshavjee; Christopher D Morgan; Sylvia L Asa; Shereen Ezzat; Jeremy Gilbert Journal: Endocr Pathol Date: 2014-09 Impact factor: 3.943
Authors: Ivana Jochmanova; April Melody T Abcede; Ruby Jane S Guerrero; Chandy Lou P Malong; Robert Wesley; Thanh Huynh; Melissa K Gonzales; Katherine I Wolf; Abhishek Jha; Marianne Knue; Tamara Prodanov; Naris Nilubol; Leilani B Mercado-Asis; Constantine A Stratakis; Karel Pacak Journal: J Cancer Res Clin Oncol Date: 2020-02-15 Impact factor: 4.553
Authors: Paraskevi Xekouki; Ana Brennand; Ben Whitelaw; Karel Pacak; Constantine A Stratakis Journal: Horm Metab Res Date: 2018-10-01 Impact factor: 2.936